Dragnev KH, et al. - In this phase 1/2 study involving patients with confirmed advanced stage IIIB or IV NSCLC and satisfactory organ function, researchers assessed the tolerability and activity of bexarotene (a rexinoid), combined with weekly paclitaxel and monthly carboplatin. The treatment regimen comprised of carboplatin (AUC =6) and 3 doses of weekly paclitaxel (100 mg/m²) every 4 weeks and daily administration of oral bexarotene at two doses: 300 and 400 mg/m²/day. They observed that patients receiving bexarotene with weekly paclitaxel and monthly carboplatin had 43% 1-year survival. It is not justifiable to further assess this regimen in unselected patients since new classes of agents for lung cancer are available. A significant correlation between bexarotene-induced hypertriglyceridemia and survival, as shown in prior subgroup analyses, was corroborated in this study.